Phase 1 ALX2004 Antibody-Drug Conjugate Targeting EGFR in Advanced Solid Tumors

This phase 1 study evaluates ALX2004, an antibody drug conjugate targeting EGFR, in an open-label, multicenter trial featuring dose escalation, exploration, and expansion phases to determine the recommended phase 2 dose. Eligible patients include those with advanced or metastatic CRC, ESCC, HNSCC, and NSCLC who meet specific treatment criteria. Sponsored by ALX Oncology Inc., the trial represents a first-in-human investigation into a novel targeted therapy for select solid tumors.